Shattuck Labs (STTK) to Release Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) will likely be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Shattuck Labs to post earnings of ($0.38) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Trading Down 24.6 %

STTK opened at $1.44 on Thursday. The company has a 50 day moving average of $1.23 and a 200 day moving average of $1.82. The company has a market cap of $68.75 million, a PE ratio of -0.94 and a beta of 1.70. Shattuck Labs has a 12 month low of $0.94 and a 12 month high of $11.76.

Wall Street Analyst Weigh In

Several research firms recently commented on STTK. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday, November 14th. Four investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.67.

Insider Buying and Selling at Shattuck Labs

In related news, Director Redmile Group, Llc acquired 133,371 shares of the stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the transaction, the director now owns 5,539,724 shares in the company, valued at $6,924,655. This represents a 2.47 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 10.50% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.